Scopus Publication Detail
The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in Scopus. This abstract is what is used to create the fingerprint of the publication.
Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: Findings from a large national database
Anita Kumar; Ann Vanderplas; Ann S. Lacasce; Maria A. Rodriguez; Allison L. Crosby; Eva Lepisto; Myron S. Czuczman; Auayporn Nademanee; Joyce Niland; Leo I. Gordon; et al. (Profiled Author: Andrew Zelenetz)
BACKGROUND: Little is known about the utility of central nervous system (CNS) prophylaxis for diffuse large B-cell lymphoma (DLBCL) in the rituximab era. The objective of this study was to characterize patterns of CNS prophylaxis for patients who received combined rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy using the National Comprehensive Cancer Network Non-Hodgkin Lymphoma Outcomes Database, a prospective cohort study that collects clinical and outcomes data for patients at 7 participating centers. METHODS: Patients who were eligible for this analysis presented with newly diagnosed DLBCL between January 2001 and July 2008, had no evidence of baseline CNS disease, and had received R-CHOP within 180 days of diagnosis. The authors assessed incidence and covariates of prophylaxis, prophylaxis modality, and, using propensity score analysis, outcomes such as overall survival. RESULTS: Of 989 eligible patients, 117 received CNS prophylaxis (11.8%), most intrathecally (71.8%). Involvement of bone marrow, other high-risk site, >1 extranodal site, higher International Prognostic Index score, and higher stage were associated individually with the receipt of prophylaxis (all P <.0001). At a median follow-up of 2.5 years, there were 20 CNS recurrences (2% [95% confidence interval, 1.1%-2.9%]) among all patients, and overall survival was not affected by prophylaxis. CONCLUSIONS: Given the overall low rate of CNS recurrence and lack of prophylaxis-associated survival benefit, the current data called into question the practice of CNS prophylaxis in the rituximab era. Copyright © 2011 American Cancer Society.
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
S.J. Ginsberg; J.R. Anderson; A.J. Gottlieb; C.D. Bloomfield; L. Norton; M. Barcos; J.F. Holland
A randomized trial of high-dose methotrexate versus standard-dose methotrexate following cyclophosphamide, doxorubicin (Adriamycin), vincristine and prednisone with or without bleomycin in the therapy of diffuse large cell lymphoma: Preliminary report of cancer and leukemia group B study 7851NCI Monographs. 1987;(5):77-80.
Joel M. Cherlow; Peter G. Steinherz; Harland N. Sather; Paul S. Gaynon; Neil J. Grossman; John H. Kersey; Helen S. Johnstone; John C. Breneman; Michael E. Trigg; G. Denman HammondInternational Journal of Radiation Oncology, Biology, Physics. 1993;27(5):1001-1009.
Wyndham H. Wilson; Sin-Ho Jung; Pierluigi Porcu; David Hurd; Jeffrey Johnson; S. Eric Martin; Myron Czuczman; Raymond Lai; Jonathan Said; Amy Chadburn; et al.Haematologica. 2012;97(5):758-765.
Appears in this Document